Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women.

Adenocarcinoma / epidemiology Carcinoma, Squamous Cell / epidemiology Female Genetic Variation Genome, Viral Genotype Global Health High-Throughput Nucleotide Sequencing Human papillomavirus 16 / classification Humans Papillomavirus Infections / complications Phylogeny Risk Assessment Uterine Cervical Neoplasms / epidemiology Whole Genome Sequencing
Cervical cancer HPV carcinogenesis HPV epidemiology HPV genomics HPV16 Whole virus genome sequencing

Journal

Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552

Informations de publication

Date de publication:
06 2019
Historique:
received: 21 11 2018
accepted: 03 02 2019
pubmed: 10 2 2019
medline: 11 1 2020
entrez: 10 2 2019
Statut: ppublish

Résumé

Human papillomavirus (HPV)16 can be separated into genetic sub-lineages (A1-4, B1-4, C1-4, D1-4) which may have differential cervical cancer risk. A next-generation sequencing assay was used to whole-genome sequence 7116 HPV16-positive cervical samples from well-characterised international epidemiological studies, including 2076 controls, 1878 squamous cell carcinoma (SCC) and 186 adenocarcinoma/adenosquamous cell carcinoma (ADC), and to assign HPV16 sub-lineage. Logistic regression was used to estimate region-stratified country-adjusted odds ratios (OR) and 95%CI. A1 was the most globally widespread sub-lineage, with others showing stronger regional specificity (A3 and A4 for East Asia, B1-4 and C1-4 for Africa, D2 for the Americas, B4, C4 and D4 for North Africa). Increased cancer risks versus A1 were seen for A3, A4 and D (sub)lineages in regions where they were common: A3 in East Asia (OR=2.2, 95%CI:1.0-4.7); A4 in East Asia (6.6, 3.1-14.1) and North America (3.8, 1.7-8.3); and D in North (6.2, 4.1-9.3) and South/Central America (2.2, 0.8-5.7), where D lineages were also more frequent in ADC than SCC (3.2, 1.5-6.5; 12.1, 5.7-25.6, respectively). HPV16 genetic variation can strongly influence cervical cancer risk. However, burden of cervical cancer attributable to different sub-lineages worldwide is largely driven by historical HPV16 sub-lineage dispersal.

Sections du résumé

BACKGROUND
Human papillomavirus (HPV)16 can be separated into genetic sub-lineages (A1-4, B1-4, C1-4, D1-4) which may have differential cervical cancer risk.
METHODS
A next-generation sequencing assay was used to whole-genome sequence 7116 HPV16-positive cervical samples from well-characterised international epidemiological studies, including 2076 controls, 1878 squamous cell carcinoma (SCC) and 186 adenocarcinoma/adenosquamous cell carcinoma (ADC), and to assign HPV16 sub-lineage. Logistic regression was used to estimate region-stratified country-adjusted odds ratios (OR) and 95%CI.
RESULTS
A1 was the most globally widespread sub-lineage, with others showing stronger regional specificity (A3 and A4 for East Asia, B1-4 and C1-4 for Africa, D2 for the Americas, B4, C4 and D4 for North Africa). Increased cancer risks versus A1 were seen for A3, A4 and D (sub)lineages in regions where they were common: A3 in East Asia (OR=2.2, 95%CI:1.0-4.7); A4 in East Asia (6.6, 3.1-14.1) and North America (3.8, 1.7-8.3); and D in North (6.2, 4.1-9.3) and South/Central America (2.2, 0.8-5.7), where D lineages were also more frequent in ADC than SCC (3.2, 1.5-6.5; 12.1, 5.7-25.6, respectively).
CONCLUSIONS
HPV16 genetic variation can strongly influence cervical cancer risk. However, burden of cervical cancer attributable to different sub-lineages worldwide is largely driven by historical HPV16 sub-lineage dispersal.

Identifiants

DOI: 10.1016/j.pvr.2019.02.001 PMID: 30738204 PMC: PMC6374642
pubmed: 30738204
pii: S2405-8521(18)30137-X
doi: 10.1016/j.pvr.2019.02.001
pmc: PMC6374642
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-74

Informations de copyright

Copyright © 2019 International Agency for Research on Cancer. Published by Elsevier B.V. All rights reserved.

Références

J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
J Virol. 1997 Mar;71(3):2463-72
pubmed: 9032384
J Clin Microbiol. 1991 Sep;29(9):1765-72
pubmed: 1663516
Int J Gynecol Pathol. 2006 Oct;25(4):393-7
pubmed: 16990718
Cell. 2017 Sep 7;170(6):1164-1174.e6
pubmed: 28886384
J Natl Cancer Inst. 2006 Aug 2;98(15):1045-52
pubmed: 16882941
Int J Cancer. 2000 Jul 15;87(2):221-7
pubmed: 10861478
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
J Infect Dis. 2007 Jun 1;195(11):1582-9
pubmed: 17471427
J Virol. 2012 Jun;86(12):6855-61
pubmed: 22491459
Int J Cancer. 2005 Apr 10;114(3):422-5
pubmed: 15551313
J Natl Cancer Inst. 2000 Mar 15;92(6):464-74
pubmed: 10716964
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10
pubmed: 17220325
Int J Cancer. 2009 Nov 1;125(9):2151-8
pubmed: 19585494
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Cancer Res. 2003 Nov 1;63(21):7215-20
pubmed: 14612516
Gynecol Oncol. 2010 May;117(2):297-301
pubmed: 20207397
Bioinformatics. 2012 Oct 1;28(19):2520-2
pubmed: 22908215
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Int J Cancer. 2017 May 1;140(9):2092-2100
pubmed: 28187495
Br J Cancer. 2013 Jan 15;108(1):240-4
pubmed: 23169278
Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):343-51
pubmed: 11927494
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Papillomavirus Res. 2015 Dec 1;1:3-11
pubmed: 26645052
Lancet. 2005 Sep 17-23;366(9490):991-8
pubmed: 16168781
J Natl Cancer Inst. 2016 Apr 29;108(9):
pubmed: 27130930
Int J Cancer. 2009 Dec 1;125(11):2609-13
pubmed: 19569178
Cancer Med. 2016 Oct;5(10):2909-2919
pubmed: 27654117
J Natl Cancer Inst. 2001 Sep 5;93(17):1325-30
pubmed: 11535707
Virology. 2016 Jan 15;488:156-61
pubmed: 26650690
J Gen Virol. 2000 Dec;81(Pt 12):2959-2968
pubmed: 11086127
Cancer Res. 2010 Apr 15;70(8):3159-69
pubmed: 20354192
PLoS Pathog. 2018 Nov 1;14(11):e1007352
pubmed: 30383862
Mol Biol Evol. 2017 Jan;34(1):4-19
pubmed: 28025273
J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
pubmed: 7791229
Viruses. 2018 Feb 13;10(2):
pubmed: 29438321
J Natl Cancer Inst. 2001 Feb 21;93(4):315-8
pubmed: 11181779
Lancet. 1998 Oct 31;352(9138):1441-2
pubmed: 9807995

Auteurs

Gary M Clifford (GM)

International Agency for Research on Cancer, Lyon, France. Electronic address: CliffordG@iarc.fr.

Vanessa Tenet (V)

International Agency for Research on Cancer, Lyon, France. Electronic address: TenetV@iarc.fr.

Damien Georges (D)

International Agency for Research on Cancer, Lyon, France. Electronic address: GeorgesD@iarc.fr.

Laia Alemany (L)

Infections and Cancer Unit, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Institute of Biomedical Research, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. Electronic address: lalemany@iconcologia.net.

Miquel Angel Pavón (MA)

Infections and Cancer Unit, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Institute of Biomedical Research, Barcelona, Spain; CIBER en Oncología (CIBERONC), Barcelona, Spain. Electronic address: mpavon@iconcologia.net.

Zigui Chen (Z)

Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: zigui.chen@cuhk.edu.hk.

Meredith Yeager (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: yeagerm@mail.nih.gov.

Michael Cullen (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: michael.cullen@nih.gov.

Joseph F Boland (JF)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: bolandj2@mail.nih.gov.

Sara Bass (S)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: sara.bass2@nih.gov.

Mia Steinberg (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: mia.steinberg@nih.gov.

Tina Raine-Bennett (T)

Women's Health Research Institute, Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Electronic address: Tina.R.Raine-Bennett@kp.org.

Thomas Lorey (T)

Regional Laboratory, Kaiser Permanente Northern California, Oakland, CA, USA. Electronic address: thomas.lorey@kp.org.

Nicolas Wentzensen (N)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. Electronic address: wentzenn@mail.nih.gov.

Joan Walker (J)

University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: joan-walker@ouhsc.edu.

Rosemary Zuna (R)

University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: rosemary-zuna@ouhsc.edu.

Mark Schiffman (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. Electronic address: schiffmm@exchange.nih.gov.

Lisa Mirabello (L)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. Electronic address: mirabellol@mail.nih.gov.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs épidermoïdes › Carcinome épidermoïde › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Génome microbien › Génome viral › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Caractéristiques de la population › Santé › Santé mondiale › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Virus des Papillomavirus humains › Papillomavirus humain de type 16 › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Maladies sexuellement transmissibles virales › Infections à papillomavirus › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Sciences de l'information › Phylogenèse › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital féminin › Tumeurs de l'utérus › Tumeurs du col de l'utérus › Human papillomavirus 16 sub-lineage dispersal...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Séquençage du génome entier › Human papillomavirus 16 sub-lineage dispersal...